Can-Fite BioPharma Ltd. (CANF)
Score window: May. 30, 2025 to May. 29, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Apr. 1, 2026 | CORRESP | Neutral/Informational | High | Can-Fite BioPharma Ltd. has submitted a request to the SEC for the acceleration of the effectiveness of its Registration Statement on Form F-3. The company aims for the statement … | Read Filing EDGAR |
| Mar. 31, 2026 | UPLOAD | Neutral/Informational | Low | The SEC correspondence addresses Can-Fite BioPharma Ltd.'s registration statement on Form F-3 filed on March 31, 2026. The SEC has indicated that they will not review the registra… | Read Filing EDGAR |
| Jul. 24, 2025 | CORRESP | Neutral/Informational | Moderate | Can-Fite BioPharma Ltd. has submitted a request to the SEC for the acceleration of the effectiveness of its Registration Statement No. 333-288890 on Form F-1. The company aims for… | Read Filing EDGAR |
| Jul. 24, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence from H.C. Wainwright & Co., LLC to the U.S. Securities and Exchange Commission requests the acceleration of the effective date for Can-Fite BioPharma Ltd.'s reg… | Read Filing EDGAR |
| Jul. 22, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Can-Fite BioPharma Ltd.'s Form 20-F for the fiscal year ended December 31, 2024. The correspondence emphasizes that the responsibility for the … | Read Filing EDGAR |
| Jul. 17, 2025 | CORRESP | Neutral/Informational | Low | Can-Fite BioPharma Ltd. submitted a response to the SEC regarding comments on their Form 20-F for the fiscal year ended December 31, 2024. The SEC requested more detailed disclosu… | Read Filing EDGAR |
| Jul. 15, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Can-Fite BioPharma Ltd. that they do not intend to review the company's Draft Registration Statement of Form F-1 submitted on July 9, 2025. The SEC has… | Read Filing EDGAR |
| Jun. 17, 2025 | UPLOAD | Concern from SEC | High | The SEC has conducted a limited review of Can-Fite BioPharma Ltd.'s Form 20-F for the fiscal year ended December 31, 2024, focusing specifically on the financial statements and re… | Read Filing EDGAR |